Click for best price
Combination Antibody Therapy Market Size, Share 2022
Combination antibody therapy is receiving higher recognition from the oncological branch of medical science research. This is primarily due to the growing use of combination therapy over single drug treatments such as radiation or chemotherapy. In addition, companies that manufacture combination antibody drugs are actively focusing on developing superior drugs that will deliver standout results. Factors such as encouraging government policies, growing concerns over higher cancer prevalence worldwide, and increasing research and development activities coupled with heavier investments are expected to boost the overall market growth in the near future. Likewise, healthy R&D pipelines are leading towards higher product offerings and also propelling the growth of global combination antibody therapy market to a significant extent.
This report contains market size and forecasts of Combination Antibody Therapy in Global, including the following market information:
The global Combination Antibody Therapy market was valued at 37130 million in 2021 and is projected to reach US$ 62230 million by 2028, at a CAGR of 7.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Chemotherapy Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Combination Antibody Therapy include Biogen, Roche Holdings, Seattle Genetics, Amgen, Bristol-Myers Squibb, Eli Lilly, Novartis, Sanofi and Celgene and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Combination Antibody Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Combination Antibody Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Combination Antibody Therapy Market Segment Percentages, by Type, 2021 (%)
- Chemotherapy Antibody
- Antibody
- Conjugated Antibodies
- Bispecific Antibodies
Global Combination Antibody Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Combination Antibody Therapy Market Segment Percentages, by Application, 2021 (%)
- Hospitals
- Cancer Research Institutes
- Clinics
- ASCs
Global Combination Antibody Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Combination Antibody Therapy Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Combination Antibody Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Combination Antibody Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Biogen
- Roche Holdings
- Seattle Genetics
- Amgen
- Bristol-Myers Squibb
- Eli Lilly
- Novartis
- Sanofi
- Celgene
- Genmab
| Report Attributes |
Report Details |
| Report Title |
Combination Antibody Therapy Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
60 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Combination Antibody Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Combination Antibody Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Combination Antibody Therapy Overall Market Size
2.1 Global Combination Antibody Therapy Market Size: 2021 VS 2028
2.2 Global Combination Antibody Therapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Combination Antibody Therapy Players in Global Market
3.2 Top Global Combination Antibody Therapy Companies Ranked by Revenue
3.3 Global Combination Antibody Therapy Revenue by Companies
3.4 Top 3 and Top 5 Combination Antibody Therapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Combination Antibody Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Combination Antibody Therapy Players in Global Market
3.6.1 List of Global Tier 1 Combination Antibody Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Combination Antibody Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Combination Antibody Therapy Market Size Markets, 2021 & 2028
4.1.2 Chemotherapy Antibody
4.1.3 Antibody
4.1.4 Conjugated Antibodies
4.1.5 Bispecific Antibodies
4.2 By Type - Global Combination Antibody Therapy Revenue & Forecasts
4.2.1 By Type - Global Combination Antibody Therapy Revenue, 2017-2022
4.2.2 By Type - Global Combination Antibody Therapy Revenue, 2023-2028
4.2.3 By Type - Global Combination Antibody Therapy Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Combination Antibody Therapy Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Cancer Research Institutes
5.1.4 Clinics
5.1.5 ASCs
5.2 By Application - Global Combination Antibody Therapy Revenue & Forecasts
5.2.1 By Application - Global Combination Antibody Therapy Revenue, 2017-2022
5.2.2 By Application - Global Combination Antibody Therapy Revenue, 2023-2028
5.2.3 By Application - Global Combination Antibody Therapy Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Combination Antibody Therapy Market Size, 2021 & 2028
6.2 By Region - Global Combination Antibody Therapy Revenue & Forecasts
6.2.1 By Region - Global Combination Antibody Therapy Revenue, 2017-2022
6.2.2 By Region - Global Combination Antibody Therapy Revenue, 2023-2028
6.2.3 By Region - Global Combination Antibody Therapy Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Combination Antibody Therapy Revenue, 2017-2028
6.3.2 US Combination Antibody Therapy Market Size, 2017-2028
6.3.3 Canada Combination Antibody Therapy Market Size, 2017-2028
6.3.4 Mexico Combination Antibody Therapy Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Combination Antibody Therapy Revenue, 2017-2028
6.4.2 Germany Combination Antibody Therapy Market Size, 2017-2028
6.4.3 France Combination Antibody Therapy Market Size, 2017-2028
6.4.4 U.K. Combination Antibody Therapy Market Size, 2017-2028
6.4.5 Italy Combination Antibody Therapy Market Size, 2017-2028
6.4.6 Russia Combination Antibody Therapy Market Size, 2017-2028
6.4.7 Nordic Countries Combination Antibody Therapy Market Size, 2017-2028
6.4.8 Benelux Combination Antibody Therapy Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Combination Antibody Therapy Revenue, 2017-2028
6.5.2 China Combination Antibody Therapy Market Size, 2017-2028
6.5.3 Japan Combination Antibody Therapy Market Size, 2017-2028
6.5.4 South Korea Combination Antibody Therapy Market Size, 2017-2028
6.5.5 Southeast Asia Combination Antibody Therapy Market Size, 2017-2028
6.5.6 India Combination Antibody Therapy Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Combination Antibody Therapy Revenue, 2017-2028
6.6.2 Brazil Combination Antibody Therapy Market Size, 2017-2028
6.6.3 Argentina Combination Antibody Therapy Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Combination Antibody Therapy Revenue, 2017-2028
6.7.2 Turkey Combination Antibody Therapy Market Size, 2017-2028
6.7.3 Israel Combination Antibody Therapy Market Size, 2017-2028
6.7.4 Saudi Arabia Combination Antibody Therapy Market Size, 2017-2028
6.7.5 UAE Combination Antibody Therapy Market Size, 2017-2028
7 Players Profiles
7.1 Biogen
7.1.1 Biogen Corporate Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Combination Antibody Therapy Major Product Offerings
7.1.4 Biogen Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.1.5 Biogen Key News
7.2 Roche Holdings
7.2.1 Roche Holdings Corporate Summary
7.2.2 Roche Holdings Business Overview
7.2.3 Roche Holdings Combination Antibody Therapy Major Product Offerings
7.2.4 Roche Holdings Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.2.5 Roche Holdings Key News
7.3 Seattle Genetics
7.3.1 Seattle Genetics Corporate Summary
7.3.2 Seattle Genetics Business Overview
7.3.3 Seattle Genetics Combination Antibody Therapy Major Product Offerings
7.3.4 Seattle Genetics Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.3.5 Seattle Genetics Key News
7.4 Amgen
7.4.1 Amgen Corporate Summary
7.4.2 Amgen Business Overview
7.4.3 Amgen Combination Antibody Therapy Major Product Offerings
7.4.4 Amgen Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.4.5 Amgen Key News
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Corporate Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Combination Antibody Therapy Major Product Offerings
7.5.4 Bristol-Myers Squibb Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.5.5 Bristol-Myers Squibb Key News
7.6 Eli Lilly
7.6.1 Eli Lilly Corporate Summary
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly Combination Antibody Therapy Major Product Offerings
7.6.4 Eli Lilly Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.6.5 Eli Lilly Key News
7.7 Novartis
7.7.1 Novartis Corporate Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis Combination Antibody Therapy Major Product Offerings
7.7.4 Novartis Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.7.5 Novartis Key News
7.8 Sanofi
7.8.1 Sanofi Corporate Summary
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Combination Antibody Therapy Major Product Offerings
7.8.4 Sanofi Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.8.5 Sanofi Key News
7.9 Celgene
7.9.1 Celgene Corporate Summary
7.9.2 Celgene Business Overview
7.9.3 Celgene Combination Antibody Therapy Major Product Offerings
7.9.4 Celgene Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.9.5 Celgene Key News
7.10 Genmab
7.10.1 Genmab Corporate Summary
7.10.2 Genmab Business Overview
7.10.3 Genmab Combination Antibody Therapy Major Product Offerings
7.10.4 Genmab Combination Antibody Therapy Revenue in Global Market (2017-2022)
7.10.5 Genmab Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Combination Antibody Therapy Market Opportunities & Trends in Global Market
Table 2. Combination Antibody Therapy Market Drivers in Global Market
Table 3. Combination Antibody Therapy Market Restraints in Global Market
Table 4. Key Players of Combination Antibody Therapy in Global Market
Table 5. Top Combination Antibody Therapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Combination Antibody Therapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Combination Antibody Therapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Combination Antibody Therapy Product Type
Table 9. List of Global Tier 1 Combination Antibody Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Combination Antibody Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Combination Antibody Therapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Combination Antibody Therapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Combination Antibody Therapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Combination Antibody Therapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Combination Antibody Therapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Combination Antibody Therapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Combination Antibody Therapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Combination Antibody Therapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Combination Antibody Therapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Combination Antibody Therapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Combination Antibody Therapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Combination Antibody Therapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Combination Antibody Therapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Combination Antibody Therapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Combination Antibody Therapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Combination Antibody Therapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Combination Antibody Therapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Combination Antibody Therapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Combination Antibody Therapy Revenue, (US$, Mn), 2023-2028
Table 30. Biogen Corporate Summary
Table 31. Biogen Combination Antibody Therapy Product Offerings
Table 32. Biogen Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
Table 33. Roche Holdings Corporate Summary
Table 34. Roche Holdings Combination Antibody Therapy Product Offerings
Table 35. Roche Holdings Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
Table 36. Seattle Genetics Corporate Summary
Table 37. Seattle Genetics Combination Antibody Therapy Product Offerings
Table 38. Seattle Genetics Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
Table 39. Amgen Corporate Summary
Table 40. Amgen Combination Antibody Therapy Product Offerings
Table 41. Amgen Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
Table 42. Bristol-Myers Squibb Corporate Summary
Table 43. Bristol-Myers Squibb Combination Antibody Therapy Product Offerings
Table 44. Bristol-Myers Squibb Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
Table 45. Eli Lilly Corporate Summary
Table 46. Eli Lilly Combination Antibody Therapy Product Offerings
Table 47. Eli Lilly Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
Table 48. Novartis Corporate Summary
Table 49. Novartis Combination Antibody Therapy Product Offerings
Table 50. Novartis Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
Table 51. Sanofi Corporate Summary
Table 52. Sanofi Combination Antibody Therapy Product Offerings
Table 53. Sanofi Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
Table 54. Celgene Corporate Summary
Table 55. Celgene Combination Antibody Therapy Product Offerings
Table 56. Celgene Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
Table 57. Genmab Corporate Summary
Table 58. Genmab Combination Antibody Therapy Product Offerings
Table 59. Genmab Combination Antibody Therapy Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Combination Antibody Therapy Segment by Type in 2021
Figure 2. Combination Antibody Therapy Segment by Application in 2021
Figure 3. Global Combination Antibody Therapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Combination Antibody Therapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Combination Antibody Therapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Combination Antibody Therapy Revenue in 2021
Figure 8. By Type - Global Combination Antibody Therapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Combination Antibody Therapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Combination Antibody Therapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Combination Antibody Therapy Revenue Market Share, 2017-2028
Figure 12. US Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Combination Antibody Therapy Revenue Market Share, 2017-2028
Figure 16. Germany Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 17. France Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Combination Antibody Therapy Revenue Market Share, 2017-2028
Figure 24. China Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 28. India Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Combination Antibody Therapy Revenue Market Share, 2017-2028
Figure 30. Brazil Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Combination Antibody Therapy Revenue Market Share, 2017-2028
Figure 33. Turkey Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Combination Antibody Therapy Revenue, (US$, Mn), 2017-2028
Figure 37. Biogen Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Roche Holdings Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Seattle Genetics Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Amgen Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bristol-Myers Squibb Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Eli Lilly Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sanofi Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Celgene Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Genmab Combination Antibody Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
